CD56 expression in acute promyelocytic leukemia: A possible indicator of poor treatment outcome?

Journal of Clinical Oncology

Volumn 17, Issue 1, 1999, Pages 293-297

  Murray, Clinton K ^a   Estey, Elihu ^a   Paietta, Elisabeth ^a   Howard, Robin S ^a   Edenfield, William J ^a   Pierce, Sherry ^a   Mann, Karen P ^a   Bolan, Charles ^a   Byrd, John C ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; FIBRINOGEN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLAST CELL; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA REMISSION; MALE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0032923932     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.1.293     Document Type: Article

References (39)

1. Grignani F, Fagioli M, Alcalay M, et al: Acute promyelocytic leukemia: From genetics to treatment. Blood 83:10-25, 1994
2. Frankel SR, Eardley A, Heller G, et al: All-trans retinoic acid for acute promyelocytic leukemia: Results of the New York Study. Ann Intern Med 120:278-286, 1994
3. Larson RA, Kondo K, Vardiman JW, et al: Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med 76:827-841, 1984
4. Miller WH, Warrell RP, Frankel SR, et al: Novel retinoic acid receptor-alpha transcripts in acute promyelocytic leukemia responsive to all-trans-retinoic acid. J Natl Cancer Inst 82:1932-1933, 1990
5. Longo L, Pandolfi PP, Biondi A, et al: Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemias. J Exp Med 172:1571-1575, 1990
6. Elliott S, Taylor K, White S, et al: Proof of differentiative mode of action of all-trans retinoic acid in acute promyelocytic leukemia using X-linked clonal analysis. Blood 79:1916-1919, 1992
7. Tallman MS, Andersen JW, Schiffer CA, et al: All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337:1021-1028, 1997
8. Cordonnier C, Vernant JP, Brun B, et al: Acute promyelocytic leukemia in 57 previously untreated patients. Cancer 55:18-25, 1985
9. Kantarjian HM, Keating MJ, Walters RS, et al: Acute promyelocytic leukemia: M.D. Anderson Hospital experience. Am J Med 80:789-797, 1986
10. Tallman MS, Kwaan HC: Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 79:543-553, 1992
11. Estey E, Thall PF, Pierce S, et al: Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 15:483-490, 1997
12. Vahdat L, Maslak P, Miller WH, et al: Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: Impact of leukocytosis, low-dose chemotherapy. PML/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 84:3843-3849, 1994
13. Slack JL, Arthur DC, Lawrence D, et al: Secondary cytogenetic changes in acute promyelocytic leukemia: Prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene - A Cancer and Leukemia Group B study. J Clin Oncol 15:1786-1795, 1997
14. Huang W, Sun GL, Li XS, et al: Acute promyelocytic leukemia: Clinical relevance of two major PML-RAR alpha isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. Blood 82:1264-1269, 1993
15. Gallagher RE, Li YP, Rao S, et al: Characterization of acute promyelocytic leukemia cases with PML-RAR alpha break/fusion sites in PML exon 6: Identification of a subgroup with decreased in vitro responsiveness to all-trans retinoic acid. Blood 86:1540-1547, 1995
16. Gallagher RE, Willman CL, Slack JL, et al: Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: An intergroup molecular study. Blood 90:1656-1663, 1997
17. Li YP, Andersen J, Zelent A, et al: RAR alpha1/RAR alpha2-PML mRNA expression in acute promyelocytic leukemia cells: A molecular and laboratory-clinical correlative study. Blood 90:306-312, 1997
18. Paietta E, Andersen J, Gallagher R, et al: The immunophenotype of acute promyelocytic leukemia (APL): An ECOG study. Leukemia 8:1108-1112, 1994
19. Bradstock KF: The diagnostic and prognostic value of immunophenotyping in acute leukemia. Pathology 25:367-374, 1993
20. Seymour JF, Pierce SA, Kantarjian HM, et al: Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56). Leukemia 8:823-826, 1994
21. Mann KP, DeCastro CM, Liu J, et al: Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes. Am J Clin Pathol 107:653-660, 1997
22. Paietta E, Gallagher RE, Wiernik PH: Myeloid/natural killer cell acute leukemia: A previously unrecognized form of acute leukemia potentially misdiagnosed as FAB-M3 acute myeloid leukemia. Blood 84:2824-2825, 1994 (letter)
23. Coustan-Smith E, Behm FG, Hurwitz CA, et al: N-CAM (CD56) expression by CD34+ malignant myeloblasts has implications for minimal residual disease detection in acute myeloid leukemia. Leukemia 7:853-858, 1993
24. Iizuka Y, Aiso M, Oshimi K, et al: Myeloblastoma formation in acute myeloid leukemia. Leuk Res 16:665-671, 1992
25. Lotzova E, Savary CA, Totpal K, et al: Highly oncolytic adherent lymphocytes: Therapeutic relevance for leukemia. Leuk Res 15:245-254, 1991
26. Sedlmayr P, Rabinowich H, Winkelstein A, et al: Generation of adherent lymphokine activated killer (A-LAK) cells from patients with acute myelogenous leukaemia. Br J Cancer 65:222-228, 1992
27. Hurwitz CA, Raimondi SC, Head D, et al: Distinctive immunophenotypic features of t(8:21)(q22;q22) acute myeloblastic leukemia in children. Blood 80:3182-3188, 1992
28. Garin-Chesa P, Fellinger EJ, Huvos AG, et al: Immunohistochemical analysis of neural cell adhesion molecule: Differential expression in small round cell tumors of childhood and adolescents. Am J Pathol 139:275-286, 1991
29. Van Camp B, Durie BGM, Spier C, et al: Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56(NKH-1; leu-19). Blood 76:377-382, 1990
30. Krishnan K, Ross CW, Adams PT, et al: Neural cell-adhesion molecule (CD 56)-positive, t(8;21) acute myeloid leukemia (AML, M2) and granulocytic sarcoma. Ann Hematol 69:321-323, 1994
31. Scott AA, Head DR, Kopecky KJ, et al: HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: A previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3. Blood 84:244-255, 1994
32. Suzuki R, Yamamoto K, Seto M, et al: CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia: A distinct hematolymphoid disease entity. Blood 90:2417-2428, 1997
33. Baer MR, Stewart CC, Lawrence D, et al: Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood 90:1643-1648, 1997
34. Cheson BD, Cassileth PA, Head DR, et al: Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813-819, 1990
35. Mehta C, Berry G: StatXact-Turbo. Cambridge, MA, Cytel Software Corporation, 1992
36. Armitage P, Berry G: Statistical Methods in Medical Research. Boston, MA, Blackwell, 1987
37. Falanga A, Iacoviello L, Evangelista V, et al: Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid. Blood 86:1072-1081, 1995
38. Degos L, Dombret H, Chomienne C, et al: All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 85:2643-2653, 1995
39. Kanamaru A, Takemoto Y, Tanimoto M, et al: All-trans-retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia: Japan Adult Leukemia Study Group. Blood 85:1202-1206, 1995